A protocol for the 0.9% saline versus Plasma-Lyte 148 for intensive care fluid therapy (SPLIT) study

Sumeet K Reddy, Michael John Bailey, Richard W Beasley, Rinaldo Bellomo, Seton J Henderson, Diane Mackle, Colin McArthur, Jan Mehrtens, John A Myburgh, Shay P McGuinness, Alex Psirides, Paul Jeffrey Young

Research output: Contribution to journalArticleOther

Abstract

Background: 0.9 saline is the most commonly used intravenous (IV) fluid in the world. However, recent data raise the possibility that, compared with buffered crystalloid fluids such as Plasma-Lyte 148, the administration of 0.9 saline to intensive care unit patients might increase their risk of acute kidney injury (AKI). Objective: To describe the protocol for the 0.9 Saline v Plasma-Lyte 148 for ICU Fluid Therapy (SPLIT) study. Methods: This is a multicentre, cluster-randomised, double crossover feasibility study to be conducted in four New Zealand tertiary ICUs over a 28-week period and will enrol about 2300 participants. All ICU patients who need crystalloid IV fluid therapy (except those with established renal failure needing dialysis and those admitted to the ICU for palliative care) will be enrolled. Participating ICUs will be randomly assigned to 0.9 saline or Plasma-Lyte 148 as the routine crystalloid IV fluid, in a blinded fashion, in four alternating 7-week blocks. Main outcome measures: The primary outcome will be the proportion of patients who develop AKI in the ICU. Secondary outcomes will include the difference between the most recent serum creatinine level measured before study enrolment and the peak serum creatinine level in the ICU; use of renal replacement therapy; and ICU and inhospital mortality. All analyses will be conducted on an intention-to-treat basis. Results and conclusion: The SPLIT study started on 1 April 2014 and will provide preliminary data on the comparative effectiveness of using 0.9 saline v Plasma-Lyte 148 as the routine IV fluid therapy in ICU patients.
Original languageEnglish
Pages (from-to)274 - 279
Number of pages6
JournalCritical Care and Resuscitation
Volume16
Issue number4
Publication statusPublished - 2014

Cite this

Reddy, S. K., Bailey, M. J., Beasley, R. W., Bellomo, R., Henderson, S. J., Mackle, D., ... Young, P. J. (2014). A protocol for the 0.9% saline versus Plasma-Lyte 148 for intensive care fluid therapy (SPLIT) study. Critical Care and Resuscitation, 16(4), 274 - 279.
Reddy, Sumeet K ; Bailey, Michael John ; Beasley, Richard W ; Bellomo, Rinaldo ; Henderson, Seton J ; Mackle, Diane ; McArthur, Colin ; Mehrtens, Jan ; Myburgh, John A ; McGuinness, Shay P ; Psirides, Alex ; Young, Paul Jeffrey. / A protocol for the 0.9% saline versus Plasma-Lyte 148 for intensive care fluid therapy (SPLIT) study. In: Critical Care and Resuscitation. 2014 ; Vol. 16, No. 4. pp. 274 - 279.
@article{e167c2b95af04d27873464cc44e80954,
title = "A protocol for the 0.9{\%} saline versus Plasma-Lyte 148 for intensive care fluid therapy (SPLIT) study",
abstract = "Background: 0.9 saline is the most commonly used intravenous (IV) fluid in the world. However, recent data raise the possibility that, compared with buffered crystalloid fluids such as Plasma-Lyte 148, the administration of 0.9 saline to intensive care unit patients might increase their risk of acute kidney injury (AKI). Objective: To describe the protocol for the 0.9 Saline v Plasma-Lyte 148 for ICU Fluid Therapy (SPLIT) study. Methods: This is a multicentre, cluster-randomised, double crossover feasibility study to be conducted in four New Zealand tertiary ICUs over a 28-week period and will enrol about 2300 participants. All ICU patients who need crystalloid IV fluid therapy (except those with established renal failure needing dialysis and those admitted to the ICU for palliative care) will be enrolled. Participating ICUs will be randomly assigned to 0.9 saline or Plasma-Lyte 148 as the routine crystalloid IV fluid, in a blinded fashion, in four alternating 7-week blocks. Main outcome measures: The primary outcome will be the proportion of patients who develop AKI in the ICU. Secondary outcomes will include the difference between the most recent serum creatinine level measured before study enrolment and the peak serum creatinine level in the ICU; use of renal replacement therapy; and ICU and inhospital mortality. All analyses will be conducted on an intention-to-treat basis. Results and conclusion: The SPLIT study started on 1 April 2014 and will provide preliminary data on the comparative effectiveness of using 0.9 saline v Plasma-Lyte 148 as the routine IV fluid therapy in ICU patients.",
author = "Reddy, {Sumeet K} and Bailey, {Michael John} and Beasley, {Richard W} and Rinaldo Bellomo and Henderson, {Seton J} and Diane Mackle and Colin McArthur and Jan Mehrtens and Myburgh, {John A} and McGuinness, {Shay P} and Alex Psirides and Young, {Paul Jeffrey}",
year = "2014",
language = "English",
volume = "16",
pages = "274 -- 279",
journal = "Critical Care and Resuscitation",
issn = "1441-2772",
publisher = "Australasian Medical Publishing Co. Pty Ltd. (AMPCo)",
number = "4",

}

Reddy, SK, Bailey, MJ, Beasley, RW, Bellomo, R, Henderson, SJ, Mackle, D, McArthur, C, Mehrtens, J, Myburgh, JA, McGuinness, SP, Psirides, A & Young, PJ 2014, 'A protocol for the 0.9% saline versus Plasma-Lyte 148 for intensive care fluid therapy (SPLIT) study' Critical Care and Resuscitation, vol. 16, no. 4, pp. 274 - 279.

A protocol for the 0.9% saline versus Plasma-Lyte 148 for intensive care fluid therapy (SPLIT) study. / Reddy, Sumeet K; Bailey, Michael John; Beasley, Richard W; Bellomo, Rinaldo; Henderson, Seton J; Mackle, Diane; McArthur, Colin; Mehrtens, Jan; Myburgh, John A; McGuinness, Shay P; Psirides, Alex; Young, Paul Jeffrey.

In: Critical Care and Resuscitation, Vol. 16, No. 4, 2014, p. 274 - 279.

Research output: Contribution to journalArticleOther

TY - JOUR

T1 - A protocol for the 0.9% saline versus Plasma-Lyte 148 for intensive care fluid therapy (SPLIT) study

AU - Reddy, Sumeet K

AU - Bailey, Michael John

AU - Beasley, Richard W

AU - Bellomo, Rinaldo

AU - Henderson, Seton J

AU - Mackle, Diane

AU - McArthur, Colin

AU - Mehrtens, Jan

AU - Myburgh, John A

AU - McGuinness, Shay P

AU - Psirides, Alex

AU - Young, Paul Jeffrey

PY - 2014

Y1 - 2014

N2 - Background: 0.9 saline is the most commonly used intravenous (IV) fluid in the world. However, recent data raise the possibility that, compared with buffered crystalloid fluids such as Plasma-Lyte 148, the administration of 0.9 saline to intensive care unit patients might increase their risk of acute kidney injury (AKI). Objective: To describe the protocol for the 0.9 Saline v Plasma-Lyte 148 for ICU Fluid Therapy (SPLIT) study. Methods: This is a multicentre, cluster-randomised, double crossover feasibility study to be conducted in four New Zealand tertiary ICUs over a 28-week period and will enrol about 2300 participants. All ICU patients who need crystalloid IV fluid therapy (except those with established renal failure needing dialysis and those admitted to the ICU for palliative care) will be enrolled. Participating ICUs will be randomly assigned to 0.9 saline or Plasma-Lyte 148 as the routine crystalloid IV fluid, in a blinded fashion, in four alternating 7-week blocks. Main outcome measures: The primary outcome will be the proportion of patients who develop AKI in the ICU. Secondary outcomes will include the difference between the most recent serum creatinine level measured before study enrolment and the peak serum creatinine level in the ICU; use of renal replacement therapy; and ICU and inhospital mortality. All analyses will be conducted on an intention-to-treat basis. Results and conclusion: The SPLIT study started on 1 April 2014 and will provide preliminary data on the comparative effectiveness of using 0.9 saline v Plasma-Lyte 148 as the routine IV fluid therapy in ICU patients.

AB - Background: 0.9 saline is the most commonly used intravenous (IV) fluid in the world. However, recent data raise the possibility that, compared with buffered crystalloid fluids such as Plasma-Lyte 148, the administration of 0.9 saline to intensive care unit patients might increase their risk of acute kidney injury (AKI). Objective: To describe the protocol for the 0.9 Saline v Plasma-Lyte 148 for ICU Fluid Therapy (SPLIT) study. Methods: This is a multicentre, cluster-randomised, double crossover feasibility study to be conducted in four New Zealand tertiary ICUs over a 28-week period and will enrol about 2300 participants. All ICU patients who need crystalloid IV fluid therapy (except those with established renal failure needing dialysis and those admitted to the ICU for palliative care) will be enrolled. Participating ICUs will be randomly assigned to 0.9 saline or Plasma-Lyte 148 as the routine crystalloid IV fluid, in a blinded fashion, in four alternating 7-week blocks. Main outcome measures: The primary outcome will be the proportion of patients who develop AKI in the ICU. Secondary outcomes will include the difference between the most recent serum creatinine level measured before study enrolment and the peak serum creatinine level in the ICU; use of renal replacement therapy; and ICU and inhospital mortality. All analyses will be conducted on an intention-to-treat basis. Results and conclusion: The SPLIT study started on 1 April 2014 and will provide preliminary data on the comparative effectiveness of using 0.9 saline v Plasma-Lyte 148 as the routine IV fluid therapy in ICU patients.

UR - http://wellingtonicu.com/Data/Trials/SPLITSAP.pdf

M3 - Article

VL - 16

SP - 274

EP - 279

JO - Critical Care and Resuscitation

JF - Critical Care and Resuscitation

SN - 1441-2772

IS - 4

ER -